Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial - Concepedia

Concepedia

Publication | Open Access

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

DOI Full Paper Access

234

Citations

27

References

2021

Year

Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú, Gregory M. Coté, Macarena I. de la Fuente, Jennifer Clarke, Benjamin M. Ellingson,

Clinical Cancer Research

Abstract

Vorasidenib was well tolerated and showed preliminary antitumor activity in patients with recurrent or progressive nonenhancing m<i>IDH</i> LGG.

References

	Year	Citations

Page 1